Anthracyclines remain a cornerstone in cancer therapy due to their high efficacy against various malignancies. However, the development of anthracycline-induced cardiotoxicity (AIC) often limits their clinical utility and patient survivorship. For decades, researchers have attributed this damage primarily to the off-target inhibition of topoisomerase II beta (TOP2B) in heart cells. A recent breakthrough by Wang Q et al. has uncovered a more complex pathological pathway. Specifically, the study reveals that doxorubicin significantly increases TOP2B protein levels in cardiomyocytes, leading to direct functional impairment.

This upregulation of TOP2B does not merely occur as an incidental side effect; it actively drives cardiac dysfunction. The research identifies that TOP2B directly binds to SMYD1, a vital histone methyltransferase required for muscle cell health. Under normal conditions, SMYD1 maintains the integrity and function of the myocardium. When TOP2B levels rise, it disrupts SMYD1 function, creating a phenotype consistent with heart failure. Consequently, this discovery shifts our understanding from simple enzyme inhibition to a mechanism involving pathological protein accumulation.

Addressing Anthracycline-Induced Cardiotoxicity with Precision Therapy

Fortunately, this new mechanistic insight opens doors for advanced cardioprotective strategies. Researchers utilized antisense oligonucleotides (ASOs) to target and reduce TOP2B levels before chemotherapy exposure. In mouse models, TOP2B ASO pretreatment successfully prevented the pathophysiological hallmarks of cardiotoxicity. This targeted approach offers a precision medicine alternative to existing general cardioprotectants that often lack specificity. Furthermore, by focusing on TOP2B regulation, clinicians may soon be able to protect the heart without compromising the essential tumor-killing power of anthracyclines.

Frequently Asked Questions

What is the role of TOP2B in anthracycline-induced cardiotoxicity?

While anthracyclines target TOP2A to kill cancer cells, they also affect TOP2B in the heart. Recent research shows that doxorubicin causes an upregulation of TOP2B protein levels. This excess protein then interferes with the essential muscle-regulating protein SMYD1, leading to cardiomyocyte damage.

How does SMYD1 impact heart health during chemotherapy?

SMYD1 is a histone methyltransferase necessary for proper muscle cell function. The upregulation of TOP2B during anthracycline treatment disrupts the normal activity of SMYD1. This disruption contributes significantly to heart failure symptoms and the loss of cardiomyocyte integrity.

Can antisense oligonucleotides (ASOs) prevent chemotherapy-related heart damage?

Yes, preclinical data suggests that ASO pretreatment targeting TOP2B can effectively prevent the development of AIC. This offers a potential new therapeutic strategy for cancer patients to mitigate long-term cardiac risks.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Wang Q et al. Novel Mechanism of and Therapeutic Approach for Anthracycline-Induced Cardiotoxicity (AIC). Cancer Res Commun. 2026 May 08. doi: 10.1158/2767-9764.CRC-25-0511. PMID: 42102394.


2. Zhang S, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639-42.


3. Vejpongsa P, Yeh ET. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95(1):45-52.